Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Parallel-Group Treatment, Double-Blind, 2-Arm to Investigate Comparative Efficacy Safety Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects 18 to 80 Years Inclusive, Moderate to Severe Ulcerative Colitis

NCT06570772 is registered in ClinicalTrials.gov with Alvotech Swiss AG as lead sponsor.

NCT NCT06570772
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570772 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Parallel-Group Treatment, Double-Blind, 2-Arm to Investigate Comparative Efficacy Safety Immunogenicity Between Intravenous AVT16 and Entyvio® in Male and Female Subjects 18 to 80 Years Inclusive, Moderate to Severe Ulcerative Colitis
Lead sponsor
Alvotech Swiss AG
Phase
Phase 3
Overall status
Terminated
Start date
September 23, 2024
Completion date
November 25, 2025
Enrollment
301 (actual)
Sites
100

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis